Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non Small Cell Lung Cancer.

• Status: Completed
• Trial end date: 2008-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether the study drug is effective and safe in the treatment of patients with non small cell lung cancer who have already received one platinum based chemotherapy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer
• Treatments: Vatalanib

Criteria

Inclusion Criteria:

• Non small cell lung cancer, Stage IIIB or Stage IV

• One and only 1 prior platinum-based chemotherapy

• No other uncontrolled concurrent illness

• Use of highly effective birth control methods in males or females with reproductive potential

Exclusion Criteria:

• Previous participation in another trial within the last 4 weeks

• Surgery within 10 days prior to the start of study treatment

• Brain metastases

• Confirmed diagnosis of infection with the human immunodeficiency virus (HIV)

• Current treatment with warfarin sodium (Coumadin) or similar anticoagulation medication

• Breast feeding